BLK
BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
Overview
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signalling. B-cell receptor (BCR) signalling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signalling that ultimately leads to B-cell activation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Ibrutinib. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.81, genetic association 0.48, clinical 0.96).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
- 1 · What it is
BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
- 2 · What goes wrong in cancer
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signalling.
- 3 · How drugs use it
No product in this corpus aims at BLK yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:1057 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P51451 (protein name, function text, keywords and locations (REST API)); CIViC gene BLK (1 evidence items, 0 assertions, 1 variants; diseases: B-cell Acute Lymphoblastic Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000136573 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.55, non-Hodgkin lymphoma 0.56, chronic myelogenous leukaemia, BCR-ABL1 positive 0.60, myeloproliferative neoplasm 0.60, leukaemia 0.61 (GraphQL API, CC0))
Biology
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signalling. B-cell receptor (BCR) signalling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signalling that ultimately leads to B-cell activation. Signalling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signalling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Also phosphorylates the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. Location: Cell membrane (UniProt). Locus 8p23.1 (HGNC).
- Leukaemia: Open Targets association 0.61 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.60 with myeloproliferative neoplasm (MONDO_0020076)
- Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908)
- Chronic myeloid leukaemia: Open Targets association 0.60 with chronic myelogenous leukaemia, BCR-ABL1 positive (MONDO_0011996)
- Acute lymphoblastic leukaemia: Open Targets association 0.55 with acute lymphoblastic leukaemia (MONDO_0004967)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: B-cell Acute Lymphoblastic Leukaemia.
Latest papers
topQuery for this target: (TITLE:"BLK" OR ABSTRACT:"BLK" OR TITLE:"BLK proto-oncogene, Src family tyrosine kinase" OR ABSTRACT:"BLK proto-oncogene, Src family tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Blk" OR ABSTRACT:"Tyrosine-protein kinase Blk" OR TITLE:"MGC10442" OR ABSTRACT:"MGC10442") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BLK, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetFGR
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetFYN
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetSRMS
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetYES1
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetIMPDH1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetIFNAR2
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types).
- TargetNT5C2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, CIViC.
- TargetARID5B
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.